AMBRILIA BIOPHARMA AND MERCK & CO., INC. SIGN LICENSING AGREEMENT GRANTING MERCK WORLDWIDE RIGHTS TO AMBRILIA'S HIV/AIDS PROTEASE INHIBITOR PROGRAM

Ambrilia Biopharma Inc, a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, and Merck & Co., Inc., one of the world's leading pharmaceutical companies, announced that Ambrilia has entered into an exclusive licensing agreement granting Merck -- through an affiliate -- the worldwide rights to Ambrilia's HIV/AIDS protease inhibitor (PI) program. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/7207/118/)